Dalton Venture

Dalton Venture is a Shanghai-based early-stage investor focused on accelerating clinical trial validation for medical device and biopharmaceutical startups, with broader MedTech and biotech exposure at seed and Series A. The thesis emphasis on clinical validation suggests the firm positions itself as an active partner during the period when companies move from preclinical or prototype work into early human studies, where execution risk is high and operational support matters more than pure capital. Limited public information about named partners, specific portfolio commitments, and detailed fund history is available in English-language sources, so founders should plan to engage directly to confirm scope.

Check sizes range from 1 million to 5 million dollars at seed and Series A, sized to underwrite IND-enabling studies, initial clinical trial activity, regulatory consulting, and the early team additions that come with that phase. Geography centers on China with Shanghai as the operating base, embedding the firm in the country’s largest biotech and clinical research cluster. Companies operating purely outside the Chinese clinical and regulatory ecosystem will not match the thesis.

The approach is suited to scientist-founders and biopharma operators who want an investor fluent in CRO relationships, hospital trial site networks, and the practicalities of NMPA-regulated clinical pathways. Those building software-only platforms or fully consumer-facing healthcare services should look elsewhere. Initial conversations should focus on the company’s clinical roadmap, the realism of the trial milestones the round will fund, and the specific operational support Dalton offers around clinical trial execution and downstream syndicate construction for the Series B and beyond.